<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="pmc-domain-id">2745</journal-id><journal-id journal-id-type="pmc-domain">jclinmed</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12156319</article-id><article-id pub-id-type="pmcid-ver">PMC12156319.1</article-id><article-id pub-id-type="pmcaid">12156319</article-id><article-id pub-id-type="pmcaiid">12156319</article-id><article-id pub-id-type="pmid">40507588</article-id><article-id pub-id-type="doi">10.3390/jcm14113832</article-id><article-id pub-id-type="publisher-id">jcm-14-03832</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Opioid Use Disorder Significantly Increases Complications and Costs in Primary and Revision Total Knee Arthroplasty a Nationwide Analysis and the Case for Preoperative Screening</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0009-6891-6182</contrib-id><name name-style="western"><surname>Cohen Nissan</surname><given-names initials="E">Ela</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af1-jcm-14-03832" ref-type="aff">1</xref><xref rid="fn1-jcm-14-03832" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0005-1201-2783</contrib-id><name name-style="western"><surname>Berkovich</surname><given-names initials="Y">Yaara</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af1-jcm-14-03832" ref-type="aff">1</xref><xref rid="fn1-jcm-14-03832" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maman</surname><given-names initials="D">David</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af1-jcm-14-03832" ref-type="aff">1</xref><xref rid="af2-jcm-14-03832" ref-type="aff">2</xref><xref rid="c1-jcm-14-03832" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4161-6894</contrib-id><name name-style="western"><surname>Yonai</surname><given-names initials="Y">Yaniv</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-jcm-14-03832" ref-type="aff">1</xref><xref rid="af2-jcm-14-03832" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5257-3087</contrib-id><name name-style="western"><surname>Steinfeld</surname><given-names initials="Y">Yaniv</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-jcm-14-03832" ref-type="aff">1</xref><xref rid="af2-jcm-14-03832" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0005-6466-6420</contrib-id><name name-style="western"><surname>Berkovich</surname><given-names initials="Y">Yaron</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-jcm-14-03832" ref-type="aff">1</xref><xref rid="af2-jcm-14-03832" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Clement</surname><given-names initials="ND">Nicholas David</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jcm-14-03832"><label>1</label>Faculty of Medicine, Technion Israel Institute of Technology, Haifa 2611001, Israel; <email>ela.cohen@campus.technion.ac.il</email> (E.C.N.); <email>byaara@campus.technion.ac.il</email> (Y.B.); <email>yanivyonai@gmail.com</email> (Y.Y.); <email>yanivsteinfeld@gmail.com</email> (Y.S.); <email>yaron.berkovich@gmail.com</email> (Y.B.)</aff><aff id="af2-jcm-14-03832"><label>2</label>Carmel Medical Center, Haifa 3436212, Israel</aff><author-notes><corresp id="c1-jcm-14-03832"><label>*</label>Correspondence: <email>maman.david@technion.ac.il</email></corresp><fn id="fn1-jcm-14-03832"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>29</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>14</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">490401</issue-id><elocation-id>3832</elocation-id><history><date date-type="received"><day>08</day><month>5</month><year>2025</year></date><date date-type="rev-recd"><day>23</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>12</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-15 14:25:23.183"><day>15</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jcm-14-03832.pdf"/><abstract><p><bold>Background:</bold> Total knee arthroplasty (TKA) is one of the most frequently performed procedures for end-stage arthritis. Effective pain control is essential for recovery, and opioids are widely used. However, patients with opioid use disorder (OUD) may be at increased risk of complications. <bold>Methods:</bold> We analyzed 2,514,099 TKA cases from the Nationwide Inpatient Sample (2016&#8211;2019), identifying 11,785 patients with OUD. After 1:1 propensity score matching, clinical and economic outcomes were compared between OUD and non-OUD patients. <bold>Results:</bold> Patients with OUD had significantly higher odds of intraoperative fracture (OR: 6.1), DVT (OR: 5.0), pneumonia (OR: 2.5), pulmonary edema (OR: 1.6), and blood transfusion (OR: 1.5) (<italic toggle="yes">p</italic> &lt; 0.001). Mean hospital charges were higher (USD 68,687 vs. USD 60,984), and LOS was longer (2.8 vs. 2.5 days, <italic toggle="yes">p</italic> &lt; 0.001). OUD patients were more likely to undergo revision TKA at a younger age (59.6 vs. 65.4 years, <italic toggle="yes">p</italic> = 0.016), with higher infection rates and greater costs. <bold>Conclusions:</bold> Patients with OUD undergoing TKA experience more complications, higher costs, and require earlier revision. Underreporting of OUD highlights the need for improved preoperative screening.</p></abstract><kwd-group><kwd>total knee arthroplasty</kwd><kwd>opioid use disorder</kwd><kwd>Nationwide Inpatient Sample</kwd><kwd>surgical outcomes</kwd><kwd>complications</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-jcm-14-03832"><title>1. Introduction</title><p>Total knee arthroplasty (TKA) stands out as one of the most effective surgical interventions for patients suffering with advanced arthritis. It is among the most frequently performed surgical procedures worldwide, demonstrating high patient satisfaction and a markedly rising incidence [<xref rid="B1-jcm-14-03832" ref-type="bibr">1</xref>].</p><p>TKA is consistently associated with significant postoperative pain [<xref rid="B2-jcm-14-03832" ref-type="bibr">2</xref>,<xref rid="B3-jcm-14-03832" ref-type="bibr">3</xref>], which can impact early range of motion, patient satisfaction, and overall outcomes [<xref rid="B2-jcm-14-03832" ref-type="bibr">2</xref>,<xref rid="B3-jcm-14-03832" ref-type="bibr">3</xref>,<xref rid="B4-jcm-14-03832" ref-type="bibr">4</xref>,<xref rid="B5-jcm-14-03832" ref-type="bibr">5</xref>]. Opioids are effective and routinely prescribed as a standard component of pain management following TKA [<xref rid="B2-jcm-14-03832" ref-type="bibr">2</xref>,<xref rid="B3-jcm-14-03832" ref-type="bibr">3</xref>,<xref rid="B6-jcm-14-03832" ref-type="bibr">6</xref>]. However, patients with OUD often exhibit heightened opioid tolerance, therefore, the perioperative management of these patients has become an increasing challenge [<xref rid="B7-jcm-14-03832" ref-type="bibr">7</xref>,<xref rid="B8-jcm-14-03832" ref-type="bibr">8</xref>,<xref rid="B9-jcm-14-03832" ref-type="bibr">9</xref>].</p><p>Moreover, a diverse patient population is undergoing this surgery, including patients with different health conditions and functional needs. A portion of patients have a history of opioid use disorder (OUD), which introduces challenges in postoperative complications, hospital costs, hospital length of stay (LOS), and revision surgery rates [<xref rid="B9-jcm-14-03832" ref-type="bibr">9</xref>,<xref rid="B10-jcm-14-03832" ref-type="bibr">10</xref>,<xref rid="B11-jcm-14-03832" ref-type="bibr">11</xref>]. However, physicians are not required to include questions about OUD in the preoperative questionnaire.</p><p>The opioid epidemic has become a severe public health crisis, causing significant social and economic impacts [<xref rid="B12-jcm-14-03832" ref-type="bibr">12</xref>,<xref rid="B13-jcm-14-03832" ref-type="bibr">13</xref>,<xref rid="B14-jcm-14-03832" ref-type="bibr">14</xref>]. Between 2016 and 2019, the prevalence of OUD fluctuated, with an average reported rate of 1% of the United States population [<xref rid="B15-jcm-14-03832" ref-type="bibr">15</xref>]. These rates continue to rise, highlighting the widespread impact of this disorder [<xref rid="B12-jcm-14-03832" ref-type="bibr">12</xref>,<xref rid="B13-jcm-14-03832" ref-type="bibr">13</xref>,<xref rid="B15-jcm-14-03832" ref-type="bibr">15</xref>].</p><p>Previous research examining outcomes of TKA in patients with a history of OUD has been primarily based on small-scale studies, often with limited focus on postoperative complications. While the NIS is a publicly available resource, our study adds significant value by combining a modern dataset with a robust, large-scale matched analysis and an integrated economic model. Unlike prior studies that either lacked comprehensive matching or focused only on primary TKA, we uniquely assess both primary and revision TKA outcomes in patients with OUD, stratified by complication type, age at revision, and etiology. In addition, we provide a cost-effectiveness evaluation of preoperative OUD screening, which has not been addressed in the existing literature. This multifaceted approach, merging complication risk analysis, revision-specific trends, and modeled economic savings, provides a more clinically actionable framework for improving perioperative care for TKA patients with OUD.</p><p>TKA outcomes are comprehensively evaluated in patients with a history of OUD, and it is investigated whether they experience more postoperative complications, higher revision surgery rates, greater healthcare costs, and longer LOS compared to patients without OUD.</p><p>This study aims to evaluate the importance of preoperative screening for OUD and its potential impact on medical complications and healthcare costs. Identifying high-risk patients is crucial for predicting potential postoperative complications. Implementing targeted prevention strategies before and during hospitalization can significantly reduce complications and enhance patient recovery outcomes.</p><p>We hypothesize that patients with OUD undergoing TKA and revision surgery will experience more postoperative complications, higher healthcare costs, longer LOS, and higher revision surgery rates compared to those without OUD. Although preoperative screening for OUD is not currently mandatory, we think that implementing such screening could provide significant value.</p><sec><title>Research Question</title><p>Does a history of opioid use disorder independently predict worse clinical and economic outcomes in patients undergoing primary and revision total knee arthroplasty?</p></sec></sec><sec sec-type="methods" id="sec2-jcm-14-03832"><title>2. Methods</title><sec id="sec2dot1-jcm-14-03832"><title>2.1. Dataset</title><p>We conducted our analysis using the Nationwide Inpatient Sample (NIS), a publicly accessible, all-payer database that represents the largest collection of inpatient hospital data in the United States. The primary analysis was conducted in 2024. The study population consisted of individuals who underwent either primary or revision total knee arthroplasty between 1 January 2016, and 31 December 2019. All analyses utilized the sampling weights (DISCWT) provided by the NIS to produce nationally representative estimates.</p></sec><sec id="sec2dot2-jcm-14-03832"><title>2.2. Patient Identification and Exclusions</title><p>Patients undergoing primary total knee arthroplasty and revision total knee arthroplasty were selected based on corresponding ICD-10 procedure codes. Opioid use disorder (OUD) was identified using the broad ICD-10 code F11.X. Specific subcategories (F11.1X, F11.2X, etc.) comprised a negligible proportion and were not analyzed separately. To ensure the analysis focused on elective surgeries, exclusions were applied to patients with non-elective admissions, those younger than 18 years old, and those undergoing revision procedures in the primary total knee arthroplasty cohort. A separate analysis was conducted for revision total knee arthroplasty cases.</p></sec><sec id="sec2dot3-jcm-14-03832"><title>2.3. Statistical Analyses and Propensity Score Matching</title><p>To control for confounding variables and ensure comparable groups, propensity score matching was performed. A one-to-one matching algorithm was applied to pair each patient with opioid use disorder with a patient without opioid use disorder, based on demographic data, comorbidities, and payer status. This resulted in two balanced cohorts, allowing for a direct comparison of outcomes.</p><p>All statistical analyses were conducted using SPSS version 26 and MATLAB 2024. Continuous variables were compared using independent <italic toggle="yes">t</italic>-tests, whereas categorical variables were analyzed with chi-square tests. A <italic toggle="yes">p</italic>-value of less than 0.05 was considered statistically significant. Length of stay (LOS), being skewed, represents a limitation as it was analyzed using standard parametric <italic toggle="yes">t</italic>-tests. Although this approach provides practical insights, future studies should utilize non-parametric methods or regression models such as negative binomial regression for improved accuracy.</p></sec><sec id="sec2dot4-jcm-14-03832"><title>2.4. Comorbidity and Outcome Identification</title><p>Comorbidities were identified using ICD-10 codes to assess differences between total knee arthroplasty patients with and without opioid use disorder. Key clinical outcomes included length of hospital stay, total hospitalization charges, and postoperative complications such as intraoperative fractures, venous thromboembolism, pneumonia, acute kidney injury, pulmonary edema, and blood transfusion requirements. To evaluate the association between opioid use disorder and complication risk, odds ratios along with 95% confidence intervals were computed.</p></sec><sec id="sec2dot5-jcm-14-03832"><title>2.5. Revision Surgery Analysis</title><p>A separate analysis was conducted for revision total knee arthroplasty patients. The revision TKA analysis was performed by the same research team. Among these cases, 1.4 percent of patients had opioid use disorder, compared to 0.5 percent in the primary total knee arthroplasty cohort (<italic toggle="yes">p</italic> &lt; 0.001), suggesting an increased likelihood of revision among opioid users. Outcomes assessed included total hospital charges, length of stay, and the etiology of revision, with particular focus on infection rates and postoperative complications.</p></sec><sec id="sec2dot6-jcm-14-03832"><title>2.6. Cost Analysis of Universal Preoperative Urine Opioid Screening</title><p>To evaluate the cost-effectiveness of universal preoperative urine opioid screening, a cost analysis was performed. Additional hospital costs associated with opioid use disorder were compared to the estimated cost of a universal urine opioid test, set at USD 75 per patient. The financial impact was analyzed for both primary and revision total knee arthroplasty, assessing whether screening could reduce the economic burden of opioid-related complications.</p></sec><sec id="sec2dot7-jcm-14-03832"><title>2.7. Ethical Aspects</title><p>This study was exempt from institutional review board approval due to the use of de-identified data from the NIS database. Informed consent was not required, as the dataset does not contain patient-identifiable information.</p></sec></sec><sec sec-type="results" id="sec3-jcm-14-03832"><title>3. Results</title><p><xref rid="jcm-14-03832-t001" ref-type="table">Table 1</xref> presents the demographic and clinical characteristics of TKA patients with and without opioid use disorder. Patients with OUD were significantly younger (61.3 vs. 66.8 years, <italic toggle="yes">p</italic> &lt; 0.001) and had a slightly lower proportion of female patients (60.6% vs. 61.6%, <italic toggle="yes">p</italic> = 0.034). They were more likely to have Medicaid as their primary payer and less likely to have private insurance (<italic toggle="yes">p</italic> &lt; 0.001).</p><p>Comorbidities were more prevalent in the OUD group, with significantly higher rates of chronic lung disease, liver disease, and fibromyalgia (<italic toggle="yes">p</italic> &lt; 0.001). Alcohol abuse was also notably more common in OUD patients.</p><sec id="sec3dot1-jcm-14-03832"><title>3.1. A Propensity Score-Matched Evaluation of Total Knee Arthroplasty Outcomes in Patients with Versus Without Opioid Use Disorder</title><p>To minimize baseline imbalances and reduce selection bias, we employed a propensity score matching approach. This technique allowed for the comparison of TKA patients with and without opioid use disorder by aligning them on key demographic and clinical variables. Propensity score matching created statistically equivalent groups, balancing variables such as age, gender, and primary payer type, thereby minimizing confounding factors and improving the reliability of comparisons. After matching, no significant differences remained in age, gender distribution, or payer type, confirming the effectiveness of the matching process (<xref rid="jcm-14-03832-t002" ref-type="table">Table 2</xref>). The prevalence of comorbidities, including hypertension, dyslipidemia, and diabetes, was also comparable between the groups, allowing for a more accurate comparison of postoperative outcomes.</p></sec><sec id="sec3dot2-jcm-14-03832"><title>3.2. Inpatient Outcomes Among Matched TKA Patients With and Without Opioid Use Disorder</title><p>After matching based on propensity scores, notable differences persisted in hospitalization metrics between the two cohorts (<xref rid="jcm-14-03832-t003" ref-type="table">Table 3</xref>). Individuals with opioid use disorder experienced a longer mean length of stay (2.8 vs. 2.5 days, <italic toggle="yes">p</italic> &lt; 0.001) and incurred greater total hospital charges (USD 68,687 vs. USD 60,984, <italic toggle="yes">p</italic> &lt; 0.001).</p></sec><sec id="sec3dot3-jcm-14-03832"><title>3.3. Elevated Postoperative Complications in Opioid Use Disorder Patients Undergoing TKA</title><p>Even after adjusting for baseline characteristics through propensity score matching, opioid use disorder remained strongly associated with elevated rates of several postoperative complications (<xref rid="jcm-14-03832-f001" ref-type="fig">Figure 1</xref>). Patients in the OUD group had more than a sixfold increased likelihood of sustaining intraoperative fractures (OR: 6.1, 95% CI: 4.0&#8211;9.3, <italic toggle="yes">p</italic> &lt; 0.001) and a fivefold higher risk of developing deep vein thrombosis (OR: 5.0, 95% CI: 1.9&#8211;13.1, <italic toggle="yes">p</italic> &lt; 0.001).</p><p>Pulmonary issues were also more prevalent among those with OUD. The incidence of pneumonia was 2.5 times greater (OR: 2.5, 95% CI: 1.2&#8211;5.2, <italic toggle="yes">p</italic> = 0.011), while pulmonary edema occurred 1.6 times more frequently (OR: 1.6, 95% CI: 1.4&#8211;1.8, <italic toggle="yes">p</italic> &lt; 0.001). Furthermore, the OUD group showed significantly higher rates of blood transfusion (OR: 1.5, 95% CI: 1.3&#8211;1.8, <italic toggle="yes">p</italic> &lt; 0.001) and blood loss anemia (OR: 1.3, 95% CI: 1.3&#8211;1.4, <italic toggle="yes">p</italic> &lt; 0.001).</p></sec><sec id="sec3dot4-jcm-14-03832"><title>3.4. Revision TKA Outcomes in Patients With and Without Opioid Use Disorder</title><p>As shown in <xref rid="jcm-14-03832-t004" ref-type="table">Table 4</xref>, among patients undergoing revision total knee arthroplasty, those with opioid use disorder accounted for 1.4% of all cases, compared to only 0.5% in primary TKA (<italic toggle="yes">p</italic> &lt; 0.001), suggesting that opioid use disorder is associated with a significantly higher likelihood of requiring revision surgery.</p><p>OUD patients were also significantly younger at the time of revision, with an average age of 59.6 years compared to 65.4 years for non-OUD patients (<italic toggle="yes">p</italic> = 0.016), indicating a possible link between opioid use and earlier implant failure or complications necessitating revision.</p><p>Hospitalization outcomes demonstrated higher costs and longer hospital stays in the OUD group. Total charges were significantly elevated at USD 132,257 compared to USD 97,346 for non-OUD patients (<italic toggle="yes">p</italic> &lt; 0.001), and the length of stay was prolonged at 4.4 days versus 3.1 days (<italic toggle="yes">p</italic> &lt; 0.001). Age differences were addressed through logistic regression analysis to confirm that younger age independently increased revision risk, and this risk was significantly amplified by the presence of OUD. Interaction analyses highlighted significant contributions from chronic pulmonary disease, liver dysfunction, and renal dysfunction.</p></sec><sec id="sec3dot5-jcm-14-03832"><title>3.5. Primary Reasons for Revision TKA Among Patients With and Without Opioid Use Disorder</title><p><xref rid="jcm-14-03832-t005" ref-type="table">Table 5</xref> highlights that infection was the most frequent indication for revision total knee arthroplasty in both cohorts, with a significantly higher prevalence among patients with opioid use disorder (32.3% vs. 22.1%, <italic toggle="yes">p</italic> &lt; 0.001). In contrast, mechanical failure causes&#8212;such as loosening or prosthetic instability&#8212;were observed at slightly lower rates in the OUD group.</p></sec><sec id="sec3dot6-jcm-14-03832"><title>3.6. Postoperative Complications Following Revision TKA in Patients With and Without Opioid Use Disorder</title><p>As shown in <xref rid="jcm-14-03832-f002" ref-type="fig">Figure 2</xref>, patients with opioid use disorder undergoing revision TKA experienced significantly higher rates of several postoperative complications. Pulmonary edema had the highest odds ratio (OR 3.7, 95% CI 2.0&#8211;7.1, <italic toggle="yes">p</italic> &lt; 0.001), followed by deep vein thrombosis (OR 2.5, 95% CI 1.3&#8211;4.7, <italic toggle="yes">p</italic> = 0.003) and acute heart failure (OR 2.4, 95% CI 1.5&#8211;4.1, <italic toggle="yes">p</italic> &lt; 0.001). Additionally, the risk of requiring blood transfusion was significantly elevated (OR 2.1, 95% CI 1.8&#8211;2.4, <italic toggle="yes">p</italic> &lt; 0.001). Infectious complications also showed increased prevalence, with pneumonia (OR 1.9, 95% CI 1.0&#8211;3.5, <italic toggle="yes">p</italic> = 0.043) and revision due to infection (OR 1.7, 95% CI 1.6&#8211;1.8, <italic toggle="yes">p</italic> &lt; 0.001) being notably higher in OUD patients.</p></sec><sec id="sec3dot7-jcm-14-03832"><title>3.7. Cost Impact of Opioid Use Disorder on TKA and the Potential Savings of Preoperative Screening</title><p><xref rid="jcm-14-03832-f003" ref-type="fig">Figure 3</xref> illustrates the average cost impact per TKA patient associated with opioid use disorder, reflecting the additional hospital costs incurred by this population. For primary TKA, the cost impact was USD 39 per patient, while for revision TKA, the additional cost reached USD 489 per patient, highlighting the substantial economic burden of opioid use disorder in orthopedic surgery. The left columns show potential savings from preoperative screening; right columns indicate added cost due to OUD-related complications.</p><p>The red dashed line represents the estimated cost of a universal preoperative urine opioid screening test at USD 75 per patient. This visual comparison suggests that, while the additional cost burden for primary TKA is lower than the screening cost, the significantly higher cost impact in revision TKA indicates that preoperative opioid screening could be a cost-effective strategy in this population.</p></sec></sec><sec sec-type="discussion" id="sec4-jcm-14-03832"><title>4. Discussion</title><p>TKA is a widely performed surgical procedure for advanced arthritis. A subset of patients undergoing TKA has a history of opioid use disorder (OUD), a condition which can impact postoperative outcomes [<xref rid="B9-jcm-14-03832" ref-type="bibr">9</xref>,<xref rid="B10-jcm-14-03832" ref-type="bibr">10</xref>,<xref rid="B11-jcm-14-03832" ref-type="bibr">11</xref>,<xref rid="B16-jcm-14-03832" ref-type="bibr">16</xref>,<xref rid="B17-jcm-14-03832" ref-type="bibr">17</xref>,<xref rid="B18-jcm-14-03832" ref-type="bibr">18</xref>,<xref rid="B19-jcm-14-03832" ref-type="bibr">19</xref>,<xref rid="B20-jcm-14-03832" ref-type="bibr">20</xref>]. We analyzed TKA outcomes in patients with OUD using big data to assess complications, costs, and hospital stays compared to individuals without OUD.</p><sec id="sec4dot1-jcm-14-03832"><title>4.1. Key Findings and Clinical Implications</title><p>Our data reveals significant underreporting of OUD in the preoperative setting. The most important findings of this study were that patients with OUD undergoing TKA experience significantly higher rates of postoperative complications, including intraoperative fractures, deep vein thrombosis, pulmonary embolism, and pneumonia, as well as increased total hospital charges and LOS compared to patients without OUD. Furthermore, revision TKA surgeries were more prevalent among patients with OUD and occurred at a younger average age compared to those without OUD. OUD patients had a significantly higher risk of infection as the primary etiology for revision, longer LOS, and higher hospitalization costs. These findings underscore the importance of accurate preoperative identification and individualized perioperative management of OUD to improve outcomes and reduce costs in TKA care.</p><p>Orthopedic teams should be aware of the underreporting of OUD and prioritize early identification as a key step toward optimizing surgical care. Individualized perioperative protocols are recommended. Including bone health assessment, personalized pain management strategies, and modifications in surgical and pharmacological approach [<xref rid="B3-jcm-14-03832" ref-type="bibr">3</xref>,<xref rid="B5-jcm-14-03832" ref-type="bibr">5</xref>,<xref rid="B6-jcm-14-03832" ref-type="bibr">6</xref>,<xref rid="B8-jcm-14-03832" ref-type="bibr">8</xref>].</p></sec><sec id="sec4dot2-jcm-14-03832"><title>4.2. Under-Reporting of OUD in Preoperative Screening</title><p>Our analysis of data collected from the NIS between 2016 and 2019 indicates that the prevalence of OUD among TKA patients was 0.5% (<xref rid="jcm-14-03832-f001" ref-type="fig">Figure 1</xref>). However, during the same period, the estimated average prevalence of OUD in the general United States population was 1% [<xref rid="B15-jcm-14-03832" ref-type="bibr">15</xref>]. This underscores the insufficient inquiry by physicians regarding OUD, resulting in an incomplete understanding of the patient&#8217;s medical history prior to surgery, which may negatively impact both the surgical procedure and its outcomes. These findings align with the lack of a mandatory requirement for inquiring about OUD [<xref rid="B9-jcm-14-03832" ref-type="bibr">9</xref>,<xref rid="B10-jcm-14-03832" ref-type="bibr">10</xref>].</p></sec><sec id="sec4dot3-jcm-14-03832"><title>4.3. Increased Postoperative Complications and Healthcare Costs</title><p>Our research reveals an elevated risk of complications such as intraoperative fractures, deep vein thrombosis, pulmonary embolism, and pneumonia. These results are consistent with previous studies, highlighting that patients with OUD face a notably higher risk for these complications [<xref rid="B9-jcm-14-03832" ref-type="bibr">9</xref>,<xref rid="B10-jcm-14-03832" ref-type="bibr">10</xref>,<xref rid="B11-jcm-14-03832" ref-type="bibr">11</xref>,<xref rid="B20-jcm-14-03832" ref-type="bibr">20</xref>].</p><p>Total hospital charges were significantly higher for the patients with OUD compared to the patients without OUD (USD 68,687 vs. USD 60,984, <italic toggle="yes">p</italic> &lt; 0.001). Moreover, a notable disparity was observed in the LOS between patients in the OUD group compared to the non-OUD group (2.8 vs. 2.5 days, <italic toggle="yes">p</italic> &lt; 0.001). These results are consistent with previous research [<xref rid="B10-jcm-14-03832" ref-type="bibr">10</xref>,<xref rid="B16-jcm-14-03832" ref-type="bibr">16</xref>,<xref rid="B20-jcm-14-03832" ref-type="bibr">20</xref>]. Complications may arise due to direct opioid effects on bone metabolism (opioid endocrinopathy) increasing fracture risk, and through exacerbated postoperative recovery challenges due to prevalent comorbidities such as chronic pulmonary and liver diseases [<xref rid="B20-jcm-14-03832" ref-type="bibr">20</xref>,<xref rid="B21-jcm-14-03832" ref-type="bibr">21</xref>,<xref rid="B22-jcm-14-03832" ref-type="bibr">22</xref>].</p><p>This implies that patients undergoing TKA with OUD place an increased economic burden on the healthcare system, emphasizing the importance of accurately identifying all patients with OUD and mitigating the prevalence of underreporting. Confronting this issue is crucial for optimizing healthcare efficiency and improving clinical decision-making [<xref rid="B23-jcm-14-03832" ref-type="bibr">23</xref>].</p></sec><sec id="sec4dot4-jcm-14-03832"><title>4.4. Increased Risk of Intraoperative Fracture</title><p>The odds of intraoperative fracture were over six times higher in patients with OUD undergoing TKA than in patients without OUD (OR: 6.1, 95% CI: 4.0&#8211;9.3, <italic toggle="yes">p</italic> &lt; 0.001). Those findings can be attributed to opioid endocrinopathy, a condition that disrupts bone metabolism and contributes to the development of osteoporosis [<xref rid="B21-jcm-14-03832" ref-type="bibr">21</xref>,<xref rid="B22-jcm-14-03832" ref-type="bibr">22</xref>]. Moreover, as documented in the literature, patients with osteoporosis face an increased risk of intraoperative fractures during TKA [<xref rid="B21-jcm-14-03832" ref-type="bibr">21</xref>,<xref rid="B22-jcm-14-03832" ref-type="bibr">22</xref>]. These findings underscore the importance of identifying OUD preoperatively, which can influence pharmacological treatment options or necessitate modifications in the surgical approach.</p></sec><sec id="sec4dot5-jcm-14-03832"><title>4.5. Reoperations and Extended Postoperative Outcomes</title><p>OUD is associated with a higher likelihood of undergoing revision surgery. (1.4% of all cases vs. 0.5% in primary TKA (<italic toggle="yes">p</italic> &lt; 0.001). Moreover, patients with OUD were also significantly younger at the time of revision (59.6 years vs. 65.4 years (<italic toggle="yes">p</italic> = 0.016)), indicating a possible link between opioid use and earlier implant failure or complications necessitating revision. These results are consistent with previous studies 23,24]. Furthermore, revision surgeries in patients with OUD demonstrated higher costs in hospitalization (USD 132,257 vs. USD 97,346 (<italic toggle="yes">p</italic> &lt; 0.001)) and longer LOS (4.4 days vs. 3.1 days (<italic toggle="yes">p</italic> &lt; 0.001)).</p><p>In our study, infection was the primary etiology differentiating patients with OUD from those without (32.3% to 22.1%, respectively). The association between preoperative opioid use and an increased risk of infection has been documented [<xref rid="B9-jcm-14-03832" ref-type="bibr">9</xref>,<xref rid="B10-jcm-14-03832" ref-type="bibr">10</xref>,<xref rid="B20-jcm-14-03832" ref-type="bibr">20</xref>]. This correlation is likely driven by a combination of patient-related factors and socioeconomic influences. While the underlying mechanisms are not yet fully understood, existing evidence indicates that opioid use may hinder the wound healing process [<xref rid="B9-jcm-14-03832" ref-type="bibr">9</xref>,<xref rid="B10-jcm-14-03832" ref-type="bibr">10</xref>,<xref rid="B15-jcm-14-03832" ref-type="bibr">15</xref>,<xref rid="B16-jcm-14-03832" ref-type="bibr">16</xref>,<xref rid="B22-jcm-14-03832" ref-type="bibr">22</xref>]. Additional research is required to further investigate the correlation.</p></sec><sec id="sec4dot6-jcm-14-03832"><title>4.6. Limitations</title><p>This study has several limitations. The NIS database provides extensive healthcare data, but it may contain errors due to suboptimal coding, underreporting, incomplete documentation, and manual entry. Additionally, the NIS only provides data for the in-hospital period, limiting the ability to assess long-term outcomes. Future studies should include long-term follow-up to better understand the full impact of OUD history on TKA Surgery outcomes.</p><p>Another limitation is the lack of data regarding the dosage of opioid and duration of OUD within patients. Opioid endocrinopathy and wound healing processes are influenced by the intensity and chronicity of opioid use [<xref rid="B11-jcm-14-03832" ref-type="bibr">11</xref>,<xref rid="B21-jcm-14-03832" ref-type="bibr">21</xref>,<xref rid="B22-jcm-14-03832" ref-type="bibr">22</xref>,<xref rid="B24-jcm-14-03832" ref-type="bibr">24</xref>]. OUD includes a wide range of use patterns, therefore incorporating these factors might have influenced the outcomes. We acknowledge limitations regarding the lack of detailed severity distinctions within OUD subcategories (F11.X codes), potentially influencing outcomes and analysis granularity.</p><p>Despite these limitations, the strengths of this study include the use of a large, nationally representative dataset and the application of rigorous statistical methods to ensure robust and reliable results. The findings underscore the importance of early identification of individuals with OUD, both to enhance clinical outcomes and to mitigate the associated burden on healthcare systems.</p></sec></sec><sec sec-type="conclusions" id="sec5-jcm-14-03832"><title>5. Conclusions</title><p>Our study demonstrates that patients with a history of OUD experience worse postoperative outcomes, including a significantly higher risk of complications such as intraoperative fractures, thromboembolic events, pneumonia, and infections [<xref rid="B25-jcm-14-03832" ref-type="bibr">25</xref>]. These patients also incur substantially greater hospital charges, extended lengths of stay, and elevated revision surgery rates, often at a younger age and with higher associated costs and LOS. The pronounced underreporting of OUD in preoperative assessments emphasizes the need for improved screening protocols to ensure accurate patient evaluation. Surgeons should implement screening protocols for OUD to enable early identification, thereby improving surgical outcomes. Future studies should further explore the long-term impact of OUD on TKA outcomes, with particular focus on the role of opioid endocrinopathy, preoperative optimization strategies, and the management of opioid use in surgical candidates to reduce the preoperative risk of complications and enhance overall patient outcomes.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, Y.B. (Yaron Berkovich) and D.M.; writing&#8212;original draft, E.C.N., Y.B. (Yaara Berkovich) and D.M.; statistical analysis, D.M.; writing&#8212;review and editing, E.C.N. and Y.B. (Yaara Berkovich); supervision, mentoring, and project administration, Y.Y., Y.S. and Y.B. (Yaron Berkovich). All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Exempt status granted by the institutional review board, and the requirement for informed consent was waived due to the de-identified nature of the NIS dataset.</p></notes><notes><title>Informed Consent Statement</title><p>Patient consent was waived because this study used the Nationwide Inpatient Sample (NIS), a publicly available de-identified database that does not contain patient-identifiable information; thus, informed consent was not required according to HCUP guidelines.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in this article, further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">AKI</td><td align="left" valign="middle" rowspan="1" colspan="1">Acute Kidney Injury</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DVT</td><td align="left" valign="middle" rowspan="1" colspan="1">Deep Vein Thrombosis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HMO</td><td align="left" valign="middle" rowspan="1" colspan="1">Health Maintenance Organization</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICD-10</td><td align="left" valign="middle" rowspan="1" colspan="1">International Classification of Diseases, 10th Revision</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LOS</td><td align="left" valign="middle" rowspan="1" colspan="1">Length of Stay</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NIS</td><td align="left" valign="middle" rowspan="1" colspan="1">Nationwide Inpatient Sample</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OUD</td><td align="left" valign="middle" rowspan="1" colspan="1">opioid use disorder </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PE</td><td align="left" valign="middle" rowspan="1" colspan="1">Pulmonary Embolism</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TKA</td><td align="left" valign="middle" rowspan="1" colspan="1">Total Knee Arthroplasty</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-jcm-14-03832"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harary</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Moschetti</surname><given-names>W.E.</given-names></name></person-group><article-title>Patient Satisfaction Is Nearly 90% After Total Knee Arthroplasty; We Are Better Than We Were</article-title><source>J. Arthroplast.</source><year>2025</year><volume>40</volume><fpage>1521</fpage><lpage>1525.e1</lpage><pub-id pub-id-type="doi">10.1016/j.arth.2024.11.038</pub-id><pub-id pub-id-type="pmid">39581239</pub-id></element-citation></ref><ref id="B2-jcm-14-03832"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christensen</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Rondon</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Vasquez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Parvizi</surname><given-names>J.</given-names></name></person-group><article-title>Opioid Use During Hospitalization Following Total Knee Arthroplasty: Trends in Consumption from 2016 to 2021</article-title><source>J. Arthroplast.</source><year>2023</year><volume>38</volume><fpage>S26</fpage><lpage>S31</lpage><pub-id pub-id-type="doi">10.1016/j.arth.2023.03.074</pub-id><pub-id pub-id-type="pmid">37019314</pub-id></element-citation></ref><ref id="B3-jcm-14-03832"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moghadam</surname><given-names>S.A.G.</given-names></name><name name-style="western"><surname>Norouzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vafaei</surname><given-names>A.</given-names></name><name name-style="western"><surname>Riazi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghodraty</surname><given-names>M.R.</given-names></name></person-group><article-title>Comparing Apotel and Remifentanil for Multimodal Patient-Controlled Analgesia in Postoperative Pain Management Following Total Knee Arthroplasty Surgery: A Randomized Controlled Trial</article-title><source>Anesthesiol. Pain Med.</source><year>2024</year><volume>14</volume><fpage>e141975</fpage><pub-id pub-id-type="doi">10.5812/aapm-141975</pub-id><pub-id pub-id-type="pmcid">PMC11088846</pub-id><pub-id pub-id-type="pmid">38741899</pub-id></element-citation></ref><ref id="B4-jcm-14-03832"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.S.</given-names></name></person-group><article-title>Does Central Sensitization Affect Hyperalgesia After Staged Bilateral Total Knee Arthroplasty? A Randomized Controlled Trial</article-title><source>J. Int. Med. Res.</source><year>2020</year><volume>48</volume><fpage>0300060520938934</fpage><pub-id pub-id-type="doi">10.1177/0300060520938934</pub-id><pub-id pub-id-type="pmid">32924685</pub-id><pub-id pub-id-type="pmcid">PMC8580502</pub-id></element-citation></ref><ref id="B5-jcm-14-03832"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Combining Various Acupuncture Therapies with Multimodal Analgesia to Enhance Postoperative Pain Management Following Total Knee Arthroplasty: A Network Meta-Analysis of Randomized Controlled Trials</article-title><source>Front. Neurol.</source><year>2024</year><volume>15</volume><elocation-id>1361037</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2024.1361037</pub-id><pub-id pub-id-type="pmid">38562427</pub-id><pub-id pub-id-type="pmcid">PMC10984270</pub-id></element-citation></ref><ref id="B6-jcm-14-03832"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wixson</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Orozco</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Colman</surname><given-names>M.W.</given-names></name></person-group><article-title>Pain and Opioid Use Following Total Knee Arthroplasty: Psycho-Social Factors Are More Predictive Than Pharmacogenomics</article-title><source>J. Arthroplast.</source><year>2024</year><volume>39</volume><fpage>1214</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1016/j.arth.2023.12.011</pub-id><pub-id pub-id-type="pmid">38081553</pub-id></element-citation></ref><ref id="B7-jcm-14-03832"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaidi</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Malpani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brundage</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Jella</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Sochacki</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Hevesi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barlow</surname><given-names>D.R.</given-names></name></person-group><article-title>Opioid Prescription Consumption Patterns After Total Joint Arthroplasty in Chronic Opioid Users Versus Opioid Naive Patients. JAAOS Glob</article-title><source>Res. Rev.</source><year>2020</year><volume>4</volume><fpage>e20</fpage><pub-id pub-id-type="doi">10.5435/JAAOSGlobal-D-20-00029</pub-id><pub-id pub-id-type="pmcid">PMC7322780</pub-id><pub-id pub-id-type="pmid">32656479</pub-id></element-citation></ref><ref id="B8-jcm-14-03832"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyland</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Brockhaus</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Spence</surname><given-names>N.Z.</given-names></name><name name-style="western"><surname>Lucki</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Howkins</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Cleary</surname><given-names>R.K.</given-names></name></person-group><article-title>Perioperative Pain Management and Opioid Stewardship: A Practical Guide</article-title><source>Healthcare</source><year>2021</year><volume>9</volume><elocation-id>333</elocation-id><pub-id pub-id-type="doi">10.3390/healthcare9030333</pub-id><pub-id pub-id-type="pmid">33809571</pub-id><pub-id pub-id-type="pmcid">PMC8001960</pub-id></element-citation></ref><ref id="B9-jcm-14-03832"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Hooten</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Warner</surname><given-names>D.O.</given-names></name></person-group><article-title>Impact of Preoperative Opioid Use on Total Knee Arthroplasty Outcomes</article-title><source>J. Bone Jt. Surg. Am.</source><year>2017</year><volume>99</volume><fpage>803</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.2106/JBJS.16.01200</pub-id><pub-id pub-id-type="pmcid">PMC5426402</pub-id><pub-id pub-id-type="pmid">28509820</pub-id></element-citation></ref><ref id="B10-jcm-14-03832"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blevins Peratikos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tippens</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>C.L.</given-names></name></person-group><article-title>Effect of Preoperative Opioid Use on Adverse Outcomes, Medical Spending, and Persistent Opioid Use Following Elective Total Joint Arthroplasty in the United States: A Large Retrospective Cohort Study of Administrative Claims Data</article-title><source>Pain Med.</source><year>2020</year><volume>21</volume><fpage>521</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1093/pm/pnz083</pub-id><pub-id pub-id-type="pmid">31120529</pub-id><pub-id pub-id-type="pmcid">PMC7060398</pub-id></element-citation></ref><ref id="B11-jcm-14-03832"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brock</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.N.</given-names></name></person-group><article-title>Prediction of Complications, Readmission, and Revision Surgery Based on Duration of Preoperative Opioid Use: Analysis of Major Joint Replacement and Lumbar Fusion</article-title><source>J. Bone Jt. Surg. Am.</source><year>2019</year><volume>101</volume><fpage>384</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.2106/JBJS.18.00502</pub-id><pub-id pub-id-type="pmid">30845032</pub-id></element-citation></ref><ref id="B12-jcm-14-03832"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humphreys</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shover</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Bohnert</surname><given-names>A.S.B.</given-names></name><name name-style="western"><surname>Brandeau</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Caulkins</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Cu&#233;llar</surname><given-names>M.-F.</given-names></name><name name-style="western"><surname>Hurd</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Juurlink</surname><given-names>D.N.</given-names></name><etal/></person-group><article-title>Responding to the Opioid Crisis in North America and Beyond: Recommendations of the Stanford&#8211;Lancet Commission</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>555</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02252-2</pub-id><pub-id pub-id-type="pmid">35122753</pub-id><pub-id pub-id-type="pmcid">PMC9261968</pub-id></element-citation></ref><ref id="B13-jcm-14-03832"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Roz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Loredo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Aston</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Metrik</surname><given-names>J.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Balodis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Secades-Villa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Belisario</surname><given-names>K.</given-names></name><name name-style="western"><surname>MacKillop</surname><given-names>J.</given-names></name></person-group><article-title>The Opioid Epidemic: A Worldwide Exploratory Study Using the WHO Pharmacovigilance Database</article-title><source>Addiction</source><year>2023</year><volume>118</volume><fpage>771</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1111/add.16075</pub-id><pub-id pub-id-type="pmid">36331523</pub-id></element-citation></ref><ref id="B14-jcm-14-03832"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Heng</surname><given-names>C.</given-names></name></person-group><article-title>The Public Health Approach to the Worsening Opioid Crisis in the United States Calls for Harm Reduction Strategies to Mitigate the Harm from Opioid Addiction and Overdose Deaths</article-title><source>Mil. Med.</source><year>2022</year><volume>187</volume><fpage>244</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1093/milmed/usab485</pub-id><pub-id pub-id-type="pmid">34908134</pub-id></element-citation></ref><ref id="B15-jcm-14-03832"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krawczyk</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Jent</surname><given-names>V.</given-names></name><name name-style="western"><surname>Keyes</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Cerd&#225;</surname><given-names>M.</given-names></name></person-group><article-title>Has the Treatment Gap for Opioid Use Disorder Narrowed in the U.S.?: A Yearly Assessment from 2010 to 2019</article-title><source>Int. J. Drug Policy</source><year>2022</year><volume>110</volume><fpage>103786</fpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2022.103786</pub-id><pub-id pub-id-type="pmid">35934583</pub-id><pub-id pub-id-type="pmcid">PMC10976290</pub-id></element-citation></ref><ref id="B16-jcm-14-03832"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Hannon</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Fillingham</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Della Valle</surname><given-names>C.J.</given-names></name></person-group><article-title>Preoperative Opioid Use Is a Risk Factor for Complication and Increased Healthcare Utilization Following Revision Total Knee Arthroplasty</article-title><source>Knee</source><year>2020</year><volume>27</volume><fpage>1121</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1016/j.knee.2020.05.013</pub-id><pub-id pub-id-type="pmid">32711872</pub-id></element-citation></ref><ref id="B17-jcm-14-03832"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bhave</surname><given-names>A.</given-names></name><name name-style="western"><surname>Geller</surname><given-names>J.A.</given-names></name></person-group><article-title>Preoperative Chronic Opioid Use and Its Effects on Total Knee Arthroplasty Outcomes</article-title><source>J. Knee Surg.</source><year>2020</year><volume>33</volume><fpage>306</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1055/s-0039-1678538</pub-id><pub-id pub-id-type="pmid">30743271</pub-id></element-citation></ref><ref id="B18-jcm-14-03832"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mahamid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yonai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Berkovich</surname><given-names>Y.</given-names></name></person-group><article-title>Comparing Complication Rates, Costs, and Length of Stay between Unicompartmental and Total Knee Arthroplasty: Insights from a Big Data Analysis Using the National Inpatient Sample Dataset</article-title><source>J. Clin. Med.</source><year>2024</year><volume>13</volume><elocation-id>3888</elocation-id><pub-id pub-id-type="doi">10.3390/jcm13133888</pub-id><pub-id pub-id-type="pmid">38999453</pub-id><pub-id pub-id-type="pmcid">PMC11242701</pub-id></element-citation></ref><ref id="B19-jcm-14-03832"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fournier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Steinfeld</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Berkovich</surname><given-names>Y.</given-names></name></person-group><article-title>Etiology, Outcomes, and Complications of Total Hip Arthroplasty in Younger Patients: A Nationwide Big Data Analysis</article-title><source>J. Clin. Med.</source><year>2024</year><volume>13</volume><elocation-id>4535</elocation-id><pub-id pub-id-type="doi">10.3390/jcm13154535</pub-id><pub-id pub-id-type="pmid">39124801</pub-id><pub-id pub-id-type="pmcid">PMC11313375</pub-id></element-citation></ref><ref id="B20-jcm-14-03832"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pagan</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>D&#8217;Apuzzo</surname><given-names>M.R.</given-names></name></person-group><article-title>Chronic Opioid Use Independently Increases Complications and Resource Utilization After Primary Total Joint Arthroplasty</article-title><source>J. Arthroplast.</source><year>2023</year><volume>38</volume><fpage>1004</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1016/j.arth.2022.12.021</pub-id><pub-id pub-id-type="pmid">36529200</pub-id></element-citation></ref><ref id="B21-jcm-14-03832"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bogler</surname><given-names>O.</given-names></name><name name-style="western"><surname>Incze</surname><given-names>M.A.</given-names></name></person-group><article-title>Endocrine Adverse Effects of Long-Term Opioid Use</article-title><source>JAMA Intern. Med.</source><year>2024</year><volume>184</volume><fpage>831</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2024.0863</pub-id><pub-id pub-id-type="pmid">38739403</pub-id></element-citation></ref><ref id="B22-jcm-14-03832"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karavitaki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boguszewski</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Colao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cundy</surname><given-names>T.</given-names></name><name name-style="western"><surname>Danese</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Fleseriu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gadelha</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Ghigo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shalet</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Veldhuis</surname><given-names>J.D.</given-names></name></person-group><article-title>Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement</article-title><source>Endocr. Rev.</source><year>2024</year><volume>45</volume><fpage>773</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1210/endrev/bnae023</pub-id><pub-id pub-id-type="pmid">39441725</pub-id></element-citation></ref><ref id="B23-jcm-14-03832"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shichman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Roof</surname><given-names>M.</given-names></name><name name-style="western"><surname>Askew</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nherera</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rozell</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Seyler</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Schwarzkopf</surname><given-names>R.</given-names></name></person-group><article-title>Projections and Epidemiology of Primary Hip and Knee Arthroplasty in Medicare Patients to 2040&#8211;2060</article-title><source>JBJS Open Access</source><year>2023</year><volume>8</volume><fpage>e22.00112</fpage><pub-id pub-id-type="doi">10.2106/JBJS.OA.22.00112</pub-id><pub-id pub-id-type="pmcid">PMC9974080</pub-id><pub-id pub-id-type="pmid">36864906</pub-id></element-citation></ref><ref id="B24-jcm-14-03832"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bali</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wise</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Batki</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Kanaya</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Wiebe</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>C.A.</given-names></name></person-group><article-title>Assessing Men with Opioid Use Disorder for Testosterone Deficiency after the Development of Symptoms</article-title><source>J. Addict. Dis.</source><year>2024</year><volume>43</volume><fpage>179</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1080/10550887.2024.2327751</pub-id><pub-id pub-id-type="pmid">38619057</pub-id></element-citation></ref><ref id="B25-jcm-14-03832"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name></person-group><article-title>The Primary Total Knee Arthroplasty: A Global Analysis</article-title><source>J. Orthop. Surg. Res.</source><year>2020</year><volume>15</volume><fpage>190</fpage><pub-id pub-id-type="doi">10.1186/s13018-020-01707-5</pub-id><pub-id pub-id-type="pmid">32456654</pub-id><pub-id pub-id-type="pmcid">PMC7249396</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="jcm-14-03832-f001" orientation="portrait"><label>Figure 1</label><caption><p>Odds of each postoperative complication following TKA in matched OUD vs. non-OUD patients.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-14-03832-g001.jpg"/></fig><fig position="float" id="jcm-14-03832-f002" orientation="portrait"><label>Figure 2</label><caption><p>Odds of each postoperative complication following revision TKA OUD vs. non-OUD patients.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-14-03832-g002.jpg"/></fig><fig position="float" id="jcm-14-03832-f003" orientation="portrait"><label>Figure 3</label><caption><p>Cost impact of opioid use disorder on TKA and the potential savings of preoperative screening.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-14-03832-g003.jpg"/></fig><table-wrap position="float" id="jcm-14-03832-t001" orientation="portrait"><object-id pub-id-type="pii">jcm-14-03832-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographic, payer characteristics, and comorbidity comparison in TKA patients with and without opioid use disorder.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No Opioid Use Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Opioid Use Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total Procedures</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,502,314 (99.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,785 (0.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean Patient Age (years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female Sex (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.034</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insurance Type&#8212;Medicare (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54.4</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insurance Type&#8212;Medicaid (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insurance Type&#8212;Private/HMO (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insurance Type&#8212;Self-pay (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insurance Type&#8212;No Charge (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insurance Type&#8212;Other (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypertensive Disease (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid Metabolism Disorders (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sleep Apnea Syndrome (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic Blood Loss Anemia (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alcohol Use Disorder (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fragility Fracture Risk (Osteoporosis) (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parkinsonian Syndromes (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.825</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurocognitive Disorders (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.978</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Renal Dysfunction (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Congestive Cardiac Failure (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic Pulmonary Disease (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior Myocardial Infarction (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetes (any type) (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.022</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatic Dysfunction (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fibromyalgia Diagnosis (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endocrine&#8212;Thyroid Disorders (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.825</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jcm-14-03832-t002" orientation="portrait"><object-id pub-id-type="pii">jcm-14-03832-t002_Table 2</object-id><label>Table 2</label><caption><p>Propensity score-matched comparison of TKA patients with and without opioid use disorder.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No Opioid Use Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Opioid Use Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total Procedures</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,785</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,785</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean Patient Age (years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.59</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female Sex (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.51</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insurance Type&#8212;Medicare (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54.4</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">p</italic> = 0.91</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insurance Type&#8212;Medicaid (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insurance Type&#8212;Private/HMO (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insurance Type&#8212;Self-pay (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insurance Type&#8212;No Charge (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insurance Type&#8212;Other (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypertensive Disease (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.36</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid Metabolism Disorders (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.28</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sleep Apnea Syndrome (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.93</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic Blood Loss Anemia (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.99</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alcohol Use Disorder (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fragility Fracture Risk (Osteoporosis) (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parkinsonian Syndromes (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.86</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurocognitive Disorders (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Renal Dysfunction (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.33</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Congestive Cardiac Failure (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.46</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic Pulmonary Disease (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.08</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior Myocardial Infarction (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.12</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetes (any type) (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.16</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatic Dysfunction (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.38</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fibromyalgia Diagnosis (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endocrine&#8212;Thyroid Disorders (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.07</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jcm-14-03832-t003" orientation="portrait"><object-id pub-id-type="pii">jcm-14-03832-t003_Table 3</object-id><label>Table 3</label><caption><p>Hospitalization outcomes in propensity score-matched TKA patients with and without opioid use disorder.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No Opioid Use Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Opioid Use Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean LOS in days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5 (S.D 1.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.8 (S.D 3.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mean charges in $</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60,984 (S.D 36,232)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68,687 (S.D 41472)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> &lt; 0.001</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jcm-14-03832-t004" orientation="portrait"><object-id pub-id-type="pii">jcm-14-03832-t004_Table 4</object-id><label>Table 4</label><caption><p>Revision TKA outcomes in patients with and without opioid use disorder.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Revision Surgery</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No Opioid Use Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Opioid Use Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total numbers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">220,215 (98.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3030 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age at Revision (Years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.4 (Std Deviation 10.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.6 (Std Deviation 10.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.016</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total charges (USD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97,346 (Std Deviation 76,718)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132,257 (Std Deviation 413,396)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Length of stay (Days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.1 (Std Deviation 2.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.4 (Std Deviation 5.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> &lt; 0.001</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jcm-14-03832-t005" orientation="portrait"><object-id pub-id-type="pii">jcm-14-03832-t005_Table 5</object-id><label>Table 5</label><caption><p>Etiology of revision in patients with and without opioid use disorder.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Etiology for Revision</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No Opioid Use Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Opioid Use Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.1%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.3%</td><td rowspan="11" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mechanical Loosening</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.0%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.0%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.4%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.6%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Instability of Prosthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.1%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.1%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wear of Articular Surface</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.1%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Periprosthetic Fracture</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fibrosis due to Prosthetic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broken Prosthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.1%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wound complication</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mechanical Complication</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.5%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.9%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other/Unspecified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.6%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.8%</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>